Quotient and Ipsen extend partnership for ultra-rare disease therapy
The agreement includes Ipsen’s investment in additional equipment at Quotient Sciences’ facility in Boothwyn, Pennsylvania, US.
Drug Development
IQVIA to acquire Charles River drug discovery assets
Novo Nordisk and Vivtex collaborate for oral medicines development
Slate Medicines raises $130m in funds to progress anti-PACAP treatments
NorthX Biologics and Demeetra collaborate on GMP manufacturing and CLD
FDA accepts Beren Therapeutics’ NDA for Niemann-Pick disease
AstraZeneca’s Calquence plus venetoclax gains approval in US to treat CLL
Roche receives FDA acceptance for giredestrant combo NDA
